Will the Amplifon-GN Deal Redraw the U.S. Hearing Aid Map?

No actionable change for individual clinical practice yet — but independent clinic owners and dispensers should monitor deal progress, as vertical integration could affect product access and pricing terms.

Vertical integration of a dominant retail chain with a top-five manufacturer could constrain independent audiologists' access to ReSound/Jabra products and shift competitive power in the U.S. market.

1. 01Analysis explores how the Amplifon–GN deal could restructure the U.S. hearing aid competitive landscape.
2. 02GN's retail brands (Beltone, Miracle-Ear) and manufacturing brands (ReSound, Jabra) give Amplifon cross-market reach.
3. 03Independent hearing care providers may face reduced access or less favorable terms for GN products post-merger.
4. 04Regulatory scrutiny (antitrust review) is a key variable in whether and how the deal closes.
5. 05The deal could accelerate vertical integration trends already underway in the industry.